SkinMedica, Inc. was founded in 1999 and is headquartered in Carlsbad, California. SkinMedica, Inc. operates as a specialty pharmaceutical company that focuses on developing, acquiring, and commercializing products that treat dermatologic conditions and diseases and enhances the appearance of skin. It offers gels for the treatment of mild to moderate atopic dermatitis; creams for the reduction in growth of unwanted facial hair in women; franchises for the treatment of acne; and products for the treatment of hyperpigmentation. The company also provides anti aging products, aesthetic skin care, moisturizers, and sun protection, eye products, as well as facial and sensitive skin cleansers, rejuvenative and acne treatment toners, and skin polishers. It markets and sells prescription pharmaceutical products, and physician-dispensed and non-prescription skin care products primarily to dermatologists and pediatricians.

ACON Laboratories, Inc. company was founded in 1995 and is based in San Diego, California. ACON Laboratories has a contracted manufacturing facility located in Hangzhou, China. ACON Laboratories, Inc. engages in the custom product design and contract manufacturing of diagnostic healthcare products. It offers rapid test products for fertility, infectious diseases, and drugs of abuse, as well as provides tumor markers, cardiac markers, lateral flow immunoassay products, blood glucose monitoring systems, and urinalysis products. The company also provides urinalysis reagent strips, breath alcohol detectors, antibodies test kits, urine analyzers, antibody enzyme immunoassay (EIA) test kits, hepatitis B virus EIA test kits, hepatitis C virus antibody EIA test kits, syphilis antibody EIA test kits, antigen test devices, gonorrhea and Chlamydia test strips, gonorrhea test strips, and tuberculosis test devices. In addition, it offers diagnostic rapid test products, which are used to detect pregnancy, ovulation, menopause, HCV, HIV, helicobacter pyloris, malaria, and dengue. The company supplies its products to hospitals, clinical laboratories, blood banks, and consumer outlets. ACON Laboratories sells its products through independent medical distributors in Asia, the Middle East, Africa, the Russian Federation, and Latin America.

QUATRx Pharmaceuticals hopes to capitalize on the bright ideas of others. The biopharmaceutical company acquires compounds in the pre-clinical stage from other companies and academic institutions and takes them through clinical studies then licensing them to pharma giants. The company focuses on developing new therapies for cardiovascular, endocrine, and metabolic conditions. Products in clinical trials include treatments for age-related hormone deficiencies in women and men as well as drugs for high cholesterol and the treatment of psoriasis. Hormos Medical, QUATRx's Finnish subsidiary, conducts most of its preclinical and discovery programs.

China DongSheng International manufactures nutritional supplements and air purifiers. Founded in 1991 as PaperClip Imaging Software, the company's original business was document management software development. After a 2006 reverse merger with American Sunrise International (the holding company of China-based Jilin Dongsheng Weiye Science & Technology Development Co.), the company changed its name to China DongSheng International and shifted its focus to natural health supplements and purifiers. Now generating the majority of its revenues from its new lines, China DongSheng plans to spin off its PaperClip operations.

Marligen Biosciences is where researchers go again and again for testing products and services. The company makes nucleic acid purification systems, genetic analysis assays, and other genomics research supplies. Its nucleic acid purification systems include rapid plasma purification systems which are used for isolation DNA so it can mapped, cloned, amplified, labeled, and sequenced. Its genetic analysis assays are sold under the Signet brand name and can screen for certain classes of DNA or be tailored to the researchers needs. Marlingen was acquired by another genetic services provider, OriGene, in 2009.

MIGENIX likes to pick up compounds after they've been discovered, and shepherd them through to late-stage clinical development. After that point, the company is happy to license them out and hopefully reap the benefits. MIGENIX has partnered with Cadence Pharmaceuticals to shoulder the cost of putting its omiganan gel through Phase III clinical trials for use in preventing catheter-related infections. Cutanea Life Sciences holds the rights to develop omiganan as an acne treatment. Other clinical and pre-clinical drug candidates in the company's pipeline include potential treatments for Hepatitis B and C, blood infections, and neuro-degenerative diseases.

Exelixis, Inc. company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California. Exelixis, Inc. discovers and develops small molecule drugs for the treatment of cancer, and various metabolic and cardiovascular disorders. Its products include XL184, a Phase 3 clinical trial compound that inhibits MET, RET, and VEGFR2, which drive tumor growth and vascularization, as well as Phase 1b/2 clinical trials compounds, including XL147 that targets phosphoinosotide-3 kinase (PI3K); and XL765, which targets PI3K and mTOR, kinases in the PI3K signaling pathway. The company has various compounds in phase 1 clinical trials, including XL518, a small molecule inhibitor of the MEK, a component of the RAS/RAF/MEK/ERK signaling pathway; XL228, which targets insulin-like growth factor type 1 receptor, an RTK in a range of human tumors; XL019 that inhibits JAK2, a cytoplasmic tyrosine; XL139, which inhibits activation of Hedgehog signaling; XL413, a small molecule inhibitor of the serine-threonine kinase CDC7; and XL888, a synthetic inhibitor of HSP90, a chaperone protein that promotes the activity and stability of a range of regulatory proteins, including kinases. In addition, its preclinical and clinical development stage products that are out-licensed to third parties for the development and commercialization include XL880, an inhibitor of MET and VEGFR2; XL281, which targets RAF, a cytoplasmic serine/threonine kinase; XL652 targeting liver X receptors, which modulate genes involved in regulation of lipid and cholesterol homeostasis; XL550, a non-steroidal mineralocorticoid receptor; and FXR Program that targets Farnesoid X Receptor, a bile acid receptor. Exelixis, Inc. has collaborations with Bristol-Myers Squibb Company; Genentech, Inc.; GlaxoSmithKline; Wyeth Pharmaceuticals; and Daiichi-Sankyo.

Merck Sharp & Dohme is the UK subsidiary of American pharmaceutical manufacturer Merck. The company markets such Merck products as arthritis pain treatment Arcoxia (which is approved in Europe but not the US), high blood pressure medication Cozaar, osteoporosis drug Fosamax, and asthma treatment Singulair. It also operates its parent's largest manufacturing facility outside the US, making about 20 medicines at its Cramlington, Northumberland, plant. Its Hoddesdon headquarters handles sales, marketing, and administrative functions; it also includes an R&D center that runs clinical trials and performs research and development activities specializing in organic and synthetic chemistry.

Genetix Group plc, along with its subsidiaries, is engaged in the design, development, manufacture and marketing of automated systems, services and consumables for cell biology, cytogenetics, pathology, proteomic and genomic research worldwide. The biopharmaceutical family of products include the ClonePixFL and associated reagents, which are used to identify the antibody clones that form the basis of pharmaceutical drugs. The ClonePix FL is also used to identify high-yielding cell lines for a customer’s production process. Its Cytovision systems are used worldwide for both pre and post natal genetic testing, and identifying certain forms of cancer, such as leukemia. Its Ariol system is used to image tissue samples from patients. Its wholly owned subsidiaries include Genetix Limited, Genescreen Limited, Genpak Limited, Genetix GmbH and Genetix KK. In April 2009, the Company acquired SlidePath Limited. In January 2010, Danaher Corporation acquired 97% interest in the Company.

Nature's Cure, Inc. company's products pair homeopathic tablets with topical treatments to heal acne and yeast infections. The over-the-counter medicines are manufactured with all-natural ingredients. The acne system is a two-part treatment; the first is a topical medication to combat existing blemishes, and the second is an oral tablet intended to prevent further acne. Its feminine care line offers a variety of yeast infection treatments (topical, oral, 1-day and 3-day) as well as a Vitality line for feminine comfort. The privately-held company was founded by formerProcter & Gamble employee Amy Baker. Its products are sold in retailers like Rite-Aid, nationwide.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.